Keywords: DYT1 TorsinA Dystonia Cholinergic interneuron Acetylcholine Conditional knock-out Electrophysiology DYT1 dystonia, a common and severe primary dystonia, is caused by a 3-bp deletion in TOR1A which encodes torsinA, a protein found in the endoplasmic reticulum. Several cellular functions are altered by the mutant protein, but at a systems level the link between these and the symptoms of the disease is unclear. The most effective known therapy for DYT1 dystonia is the use of anticholinergic drugs. Previous studies have revealed that in mice, transgenic expression of human mutant torsinA under a non-selective promoter leads to abnormal function of striatal cholinergic neurons. To investigate what pathological role torsinA plays in cholinergic neurons, we created a mouse model in which the Dyt1 gene, the mouse homolog of TOR1A, is selectively deleted in cholinergic neurons (ChKO animals). These animals do not have overt dystonia, but do have subtle motor abnormalities. There is no change in the number or size of striatal cholinergic cells or striatal acetylcholine content, uptake, synthesis, or release in ChKO mice. There are, however, striking functional abnormalities of striatal cholinergic cells, with paradoxical excitation in response to D2 receptor activation and loss of muscarinic M2/M4 receptor inhibitory function. These effects are specific for cholinergic interneurons, as recordings from nigral dopaminergic neurons revealed normal responses. Amphetamine stimulated dopamine release was also unaltered. These results demonstrate a cell-autonomous effect of Dyt1 deletion on striatal cholinergic function. Therapies directed at modifying the function of cholinergic neurons may prove useful in the treatment of the human disorder.
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Introduction
Dystonias are characterized by repetitive involuntary muscle contractions causing twisting movements (Fahn and Eldridge, 1976) . Early onset torsion dystonia (DYT1, or Oppenheim dystonia) is a genetically determined form of "primary" dystonia (Albanese et al., 2011) with autosomal dominant inheritance, reduced penetrance, and onset most often before young adulthood (Breakefield et al., 2008) . The mutation is a 3-bp deletion in the gene TOR1A, encoding torsinA (Ozelius et al., 1997), a protein expressed throughout the brain and found in the endoplasmic reticulum and nuclear envelope (Augood et al., 2003; Gonzalez-Alegre and Paulson, 2004) . TorsinA is a member of the AAA+ (ATPases Associated with a variety of cellular Activities) (Ozelius et al., 1997) , and has a number of potential functions including interactions with the cytoskeleton, binding in the nuclear envelope, chaperone activity, and vesicle transportation and secretion (Granata et al., 2009; Warner et al., 2010) .
The pathophysiology of DYT1 dystonia is thought to involve abnormalities in neural processing and plasticity. In carriers of the DYT1 mutation, there is abnormal metabolic activity in areas involved in sensorimotor processing and motor planning (Carbon and Eidelberg, 2009), abnormal synaptic plasticity following repetitive transcranial magnetic stimulation (rTMS) (Edwards et al., 2006) , and disparities in motor sequence learning (Ghilardi et al., 2003) . Structural studies suggest altered connectivity between cortex, thalamus, and cerebellum (Carbon et al., 2008) . Pathological study of DYT1 brains, however, has revealed no evidence of neurodegeneration (Rostasy et al., 2003; Standaert, 2011) , and the connection between the cellular functions of torsinA and the systems-level abnormalities is unclear (Breakefield et al., 2008) .
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Abbreviations: ChKO, cholinergic-specific conditional knock-out; ChAT, choline acetyl-transferase; Ach, acetylcholine; LCM, laser capture microdissection; ChI, cholinergic interneuron; D2, dopaminergic receptor; DA, dopamine; WT, wild type; M2/M4, muscarinic acetylcholine receptor; mGluR, metabotropic glutamate receptor.
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